Novavax Inc. Stock
€5.49
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Novavax
sharewise wants to provide you with the best news and tools for Novavax, so we directly link to the best financial data sources.
Financials
News
Novavax Stock: FDA Approval Triggers Financial Windfall
The U.S. Food and Drug Administration has granted full approval (Biologics License Application) for Novavax's COVID-19 vaccine Nuvaxovid, marking a significant breakthrough for the biotech company
Novavax Stock: Narrowing Losses Drive Market Confidence
Novavax has significantly reduced its net loss in the fourth quarter of 2024 to $81.03 million ($0.51 per share), a substantial improvement from the $178.39 million ($1.44 per share) loss reported
2 Beaten-Down Stocks That Still Aren't Worth Buying
President Trump's trade policies are sending many stocks that were performing well in the wrong direction and exacerbating things for others that were already struggling. So, the time seems ripe for
2 Beaten-Down Stocks Near Their 52-Week Lows That Aren't Worth Buying
Buying stocks after they have lost significant market value can lead to excellent returns in the long run, but only if the company in question can reverse its fortunes.
Sometimes, corporations lag